scholarly journals Exploiting cancer vulnerabilities: mTOR, autophagy, and homeostatic imbalance

2017 ◽  
Vol 61 (6) ◽  
pp. 699-710 ◽  
Author(s):  
Charlotte E. Johnson ◽  
Andrew R. Tee

Mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) at lysosomes plays a pivotal role in cell growth control where an array of large multiprotein complexes relay nutrient, energy, and growth signal inputs through mTORC1. In cancer cells, such regulation often becomes disconnected, leading to uncontrolled cell growth and an elevation in cellular stress. Consequently, cancer cells often lose homeostatic balance as they grow in unfavorable conditions, i.e. when nutrients and energy are limited yet mTORC1 is still aberrantly activated. Cancer cells lose signaling flexibility because of hyperactive mTORC1 that leads to heightened cellular stress and loss of nutrient and energy homeostasis, all of which are potential avenues for cancer therapy. Cancer cells often enhance mTORC1 to drive cell growth and proliferation, while also maintaining their survival. Autophagy regulation by mTORC1 is critically involved in nutrient and energy homeostasis, cell growth control, and survival. Studying mTORC1 and autophagy as a potential therapeutic target for cancer treatment has been the focus of a wide range of research over the past few decades. This review will explore the signaling pathways central to mTORC1 and autophagy regulation, and cancer vulnerabilities while considering anticancer therapies.

2013 ◽  
Author(s):  
Zenobia Carmel D'Costa ◽  
Catherine A. Higgins ◽  
Richard Williams ◽  
Paul B. Mullan

2013 ◽  
Vol 27 (S1) ◽  
Author(s):  
John Blenis ◽  
Alfredo Csibi ◽  
Sang Gyun Kim ◽  
Xiaoxiao Gu ◽  
Jeannie Li ◽  
...  

Cell Cycle ◽  
2014 ◽  
Vol 13 (22) ◽  
pp. 3474-3475 ◽  
Author(s):  
Joseph F Cardiello ◽  
Jennifer F Kugel ◽  
James A Goodrich

2020 ◽  
Vol 477 (15) ◽  
pp. 2893-2919
Author(s):  
Walaa E. Kattan ◽  
John F. Hancock

The three human RAS proteins are mutated and constitutively activated in ∼20% of cancers leading to cell growth and proliferation. For the past three decades, many attempts have been made to inhibit these proteins with little success. Recently; however, multiple methods have emerged to inhibit KRAS, the most prevalently mutated isoform. These methods and the underlying biology will be discussed in this review with a special focus on KRAS-plasma membrane interactions.


Author(s):  
Masahiro Kawahara ◽  
Akito Natsume ◽  
Satoshi Terada ◽  
Koichi Kato ◽  
Kouhei Tsumoto ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document